Also known as: NCI
Ivermectin is being promoted again for unproven uses like cancer and hantavirus, while several states consider making it available over the counter. Experts stress there is no clinical evidence for these uses and warn of serious side effects. Prescriptions among cancer patients have more than doubled.
A sustained telehealth program combining counseling and nicotine replacement therapy boosted 6-month smoking abstinence to 28.4% vs. 14.7% with quitline referral, a national trial found. The intervention was well-engaged and satisfied patients.
UNM Comprehensive Cancer Center installs MRI-LINAC, enabling real-time tumor tracking and adaptive radiation therapy. The system has treated 10 patients and improves precision, reducing damage to healthy tissue.
A clinical trial showed that digital symptom check-ins improved quality of life for advanced cancer patients, especially underserved groups. Researchers are also advancing survivorship care and investigating ageing biology to improve recovery in older patients.
MassBio's Align Summit 2026 returns October 15 in Boston with 50+ startups and AI drug discovery tracks. The SITC EU summit adds a pre-clinical models panel, and UCLA's Cell-Cell Symposium 2026 tackles single-cell spatial data challenges.
FDA granted early access to a pancreatic cancer drug; final ARROW data for pralsetinib in RET+ NSCLC were published. A Sarah Cannon Research Institute official outlined a tissue-agnostic vision and highlighted new oncology research.
Personalized mRNA vaccines showed promise in pancreatic cancer trials with 7 of 16 patients in remission after five years. Stage 2 melanoma patients saw a 50% decreased death risk with personalized mRNA vaccines. U.S. funding cuts and policy shifts have stalled domestic mRNA cancer research while companies move trials abroad.
Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.
At ASCO 2026, Rutgers and Ohio State researchers present new breast cancer combination data, lymphoma survival analyses, and a drug donation program that cut medication wait times to about six days.
A new U.S. clinical study will test whether provider-mediated communication of colorectal cancer genetic risk increases family genetic testing. The trial plans to enroll around 4,000 patients and relatives.
